OPKO Health/$OPK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About OPKO Health

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

Ticker

$OPK
Sector
Primary listing

Employees

2,997

OPKO Health Metrics

BasicAdvanced
$1.2B
-
-$0.26
1.19
-

What the Analysts think about OPKO Health

Analyst ratings (Buy, Hold, Sell) for OPKO Health stock.

Bulls say / Bears say

OPKO partnered with Entera Bio to develop a once-daily obesity and metabolic disorder pill, targeting a market projected to reach $150 billion by 2030, which diversifies its pipeline into a high-growth therapeutic area (Reuters).
The Board authorized a $100 million increase to its share repurchase program—bringing total capacity to $200 million—showing management’s belief in OPKO’s undervaluation and commitment to returning capital to shareholders (Nasdaq).
Gross margin improved by 315 basis points to 31.5% in Q2 2025, demonstrating improved unit economics and cost control despite revenue challenges (Nasdaq).
Full-year revenue guidance was lowered to $640 million–$660 million from the prior outlook of $675 million–$685 million, highlighting soft top-line momentum and cautious management expectations (Nasdaq).
Net loss widened significantly to $148.4 million, or $0.19 per share, in Q2 2025—driven by a $91.7 million non-recurring expense—compared to a $10.3 million loss a year earlier, increasing concerns about shareholder value (OPKO Health).
Diagnostics segment revenues dropped 21.9% year-over-year to $101.1 million in Q2 2025 (from $129.4 million), reflecting lower clinical test volumes after BioReference asset sales and weighing on recovery in that segment (OPKO Health).
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

OPKO Health Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

OPKO Health Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $OPK

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs